文献速递甲状腺疾病

未分化甲状腺癌治疗失败的模式

Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2017-02-16

这项回顾性研究纳入2013年1月至2015年10月在本机构就诊的54例未分化甲状腺癌患者,分析一线治疗与基因组检测的作用。全队列中位总生存期为11.9个月,1年生存率39%,中位治疗失败时间为3.8个月。接受手术、外照射放疗和化疗三联治疗的患者中位总生存期为22.1个月,而接受外照射放疗联合化疗双联治疗者为6.5个月(p=0.0008)。

要点

  • 全队列中位总生存期为11.9个月,1年生存率39%,中位治疗失败时间为3.8个月。
  • 三联治疗组中位总生存期为22.1个月,双联治疗组为6.5个月(p=0.0008)。
  • 男性死于未分化甲状腺癌的可能性是女性的三倍(p=0.0024)。

核心结论

  • 适合积极三联治疗的未分化甲状腺癌患者生存期改善;较短的治疗失败时间主要由远处转移所致,提示早期启动全身治疗(包括辅助或新辅助治疗)可能改善结局。

研究设计与样本

  • 回顾性研究,纳入2013年1月至2015年10月在本机构就诊的54例未分化甲状腺癌患者,采用Kaplan-Meier法计算中位总生存期和治疗失败时间。

主要发现

  • 诊断时中位年龄为63岁,29/54(54%)为女性;诊断时分期为IVC期者占50%,IVB期占32%,IVA期占18%;约93%的患者接受了体细胞基因检测。
  • 初始治疗为手术者23例,外照射放疗联合或不联合放疗增敏化疗者29例,全身化疗者2例;19例接受了全部三种治疗模式。
  • 全队列中位总生存期为11.9个月,1年生存率39%,中位治疗失败时间为3.8个月;大多数患者(74%)出现新发远处转移或现有转移病灶进展。
  • 接受手术、外照射放疗和化疗三联治疗的患者中位总生存期为22.1个月,而接受外照射放疗联合化疗双联治疗者为6.5个月(p=0.0008);两组治疗失败时间相同(分别为7.0个月和6.5个月)。
  • 男性死于未分化甲状腺癌的可能性是女性的三倍(p=0.0024);基于肿瘤大小(5 cm界值)、年龄(60岁界值)或是否存在任何突变,总生存期或治疗失败时间无差异;TP53体细胞突变患者治疗失败时间有缩短趋势。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaplastic thyroid cancer (ATC) is one of the most lethal forms of cancer with a high mortality rate. Current guidelines support surgery for resectable ATC followed by external beam radiation therapy (EBRT) with or without chemotherapy. Treatment for those who are unresectable is palliative. Our goal was to examine first-line therapies as well as the role of genomic profiling in an effort better understand how to approach ATC. METHODS: This is a retrospective study of ATC patients who were seen at our institution from January 2013 to October 2015. Median overall survival (OS) and time to treatment failure (TTF) were calculated by the Kaplan-Meier method. RESULTS: Fifty-four patients were included. Median age at diagnosis was 63 years and 29/54 (54%) were women. The majority had stage IVC disease at diagnosis (50%), followed by IVB (32%), and IVA (18%). Approximately 93% had somatic gene testing. Initial treatment was surgery in 23 patients, EBRT with or without radiosensitizing chemotherapy in 29 patients, and systemic chemotherapy in 2 patients. Nineteen patients had all three treatment modalities. For the entire cohort, median OS was 11.9 months with 39% survival at 1 year and median TTF was 3.8 months. The majority of patients (74%) developed new distant metastasis or progression of existing metastatic disease. Patients who received trimodal therapy consisting of surgery, EBRT, and chemotherapy had a median OS of 22.1 months versus 6.5 months in those who received dual therapy with EBRT and chemotherapy (p = 0.0008). The TTF was the same in the two groups (7.0 and 6.5 months, respectively). Men were three times more likely to die from ATC than women (p = 0.0024). No differences in OS or TTF were noted based on tumor size (5 cm cutoff), age (60 years cutoff), or presence of any mutation. There was a trend toward shorter TTF in patients with somatic mutations in TP53. CONCLUSION: Patients with ATC amenable to aggressive tri-modal therapy demonstrate improved survival. The short TTF, due primarily to distant metastatic disease, highlights the potential opportunity for improved outcomes with earlier initiation of systemic therapy including adjuvant or neoadjuvant therapy.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Rao SN, Zafereo M, Dadu R, et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017. PMID: 28068873. doi:10.1089/thy.2016.0395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。